Register an account to search through 14,000+ stocks! 

Ad

2070 – Saudi Pharmaceutical Industries & Medical Appliances Corporation SJSC

Ad

Compliant

★★★★★

Industry: Pharmaceuticals | Saudi

Saudi Pharmaceutical Industries & Medical Appliances Corporation SJSC is Shariah compliant. The company passes all five major Shariah standards.

Market cap: 1,056 MRev. Growth: 106.61%

AAOIFI ✓

Debt/MC11.85%
Non-Compliant Assets/MC16.04%

S&P ✓

Debt/36 mo MC10.95%
Cash/36 mo MC6.08%
AR/36 mo MC26.03%

DJIM ✓

Debt/24 mo MC9.63%
Cash/24 mo MC5.34%
AR/24 mo MC22.9%

FTSE ✓

Debt/Assets10.59%
Cash/Assets5.88%
Cash&AR/Assets31.06%

MSCI ✓

Debt/Assets10.59%
Cash/Assets5.88%
Cash&AR/Assets31.06%

Recommendation Rating

4

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 10.2

Low: 9.46

High: 10.93

Total Analysts: 1


Saudi Pharmaceutical Industries and Medical Appliances Corporation SJSC (SPIMACO) is a Saudi Arabia-based company engaged in the pharmaceutical industry sector. The Company is organized, together with its subsidiaries, into two business segments: the Medical and pharmaceutical production segment focuses on the manufacture, production, development and marketing of pharmaceutical raw materials and medical appliances, as well as the production of consumables medical appliances, and the Investment segment is engaged in investing activity in associates and investment in securities. The Company’s product pipeline includes tablets, capsules, dry powder for suspension, syrups and suspensions, injections, creams, ointments and gels, suppositories, mouthwash and antiseptic products. The Company’s manufacturing facility is located at Qassim Industrial City, about 320 kilometers north-west of Riyadh.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.

To understand how the screening is done, please read the Shariah Screening Methodology page.

Ad

Responses